GLP-1

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable drugs that mimic the GLP-1 hormone to manage type 2 diabetes and, increasingly, obesity. Brand-name drugs in the class include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), and liraglutide (Saxenda, Victoza). GLP-1 dispensing and especially compounded GLP-1 dispensing produced the most active FDA, PBM, and state board enforcement wave of the 2024 to 2026 period.

How GLP-1 enforcement works

GLP-1 enforcement runs across three tracks. FDA enforcement focuses on compounded GLP-1 preparations: the agency's shortage-list resolution for semaglutide and tirzepatide ended the period of legal large-scale compounding for those substances under section 503A and 503B. Subsequent compounding requires a clinical-significance exception or a base-substance change that places the preparation outside the FDA framework. PBM enforcement runs separately, focused on audit recoupment for GLP-1 claims where documentation gaps appear, where dispense-date timing crosses the shortage-list resolution, or where the prescription patterns suggest off-label dispensing at scale.

State board enforcement varies. Some state boards opened parallel inquiries into compounded-GLP-1 dispensing patterns. Others deferred to FDA. Where DEA jurisdiction attaches (controlled-substance pairings or peptide regulatory analysis), DEA inspection and enforcement add a third regulatory track.

When GLP-1 enforcement applies

GLP-1 enforcement applies to any pharmacy or facility dispensing GLP-1 receptor agonists, especially compounded preparations and especially during the period spanning the FDA shortage-list resolution. Specialty pharmacies, 503A compounders, 503B outsourcing facilities, telehealth-linked dispensers, and traditional retail pharmacies are all in scope. The dispense-date analysis (the date the prescription was actually dispensed relative to the shortage-list status on that date) is the central factual question in most defense matters.

The pharmacy's exposure under GLP-1 enforcement

FDA exposure runs through Form 483, Warning Letter, consent decree, and criminal referral under the Park doctrine. PBM exposure runs through audit recoupment, network termination for cause, and referral to state boards. State board exposure runs through licensure discipline. Criminal exposure runs through DEA where applicable and DOJ where the dispensing patterns support healthcare fraud or AKS theories. The defense framework focuses on the dispense-date reconstruction, the prescription-validity record, the clinical-significance exception analysis where the preparation differs materially from the commercial product, and parallel federal and state regulatory coordination.

Related terms

• REMS FDA Risk Evaluation and Mitigation Strategy programs that apply to certain GLP-1 dispensing contexts.
• Bulks list The FDA 503A and 503B bulks lists that govern which substances may be compounded, including the semaglutide and tirzepatide proposals.
• 503A and 503B The two compounding pathways whose framework drives most GLP-1 compounding enforcement.
• Specialty pharmacy The pharmacy category that often handles GLP-1 dispensing under specialty network contracts.

See also

• Practice area
  GLP-1 Compounding Defense

  The full GLP-1 compounding defense framework: dispense-date analysis, bulks-list compliance, FDA Warning Letter response.

• Practice area
  GLP-1 PBM Audit Defense

  Defense framework for PBM audits on GLP-1 claims, including OptumRx, Caremark, ESI, and Humana posture.

• Practice area
  Compounding Pharmacy Defense

  The compounding defense pillar spanning 503A and 503B regulatory pathways.